Vision Medicals

Vision Medicals (微远基因) is a Chinese molecular diagnostics company headquartered in Guangzhou that specializes in genomic testing and precision medicine for infectious diseases. According to its corporate introduction, the company was founded in 2018 and has built an AI-driven diagnostic system for infectious diseases, operating a research and production base of more than 10,000 square meters and accumulating over one million cases of pathogen big data. Its stated mission is to advance the "mNGS 2.0 era" through continued innovation across three dimensions: pathogen, drug, and host. The company's core offering is the IDseq product family, a set of metagenomic next-generation sequencing (mNGS) and targeted sequencing (tNGS) assays for pathogen detection. The flagship IDseq Prime is a classic random-sequencing mNGS product that can detect tens of thousands of pathogens — bacteria, fungi, viruses, and parasites — in a single unbiased run, and can also perform strain-level typing and resistance and virulence gene detection. IDseq Ultra combines random and probe-capture sequencing (capture-enhanced mNGS), enriching more than 3,000 important pathogens while remaining broadly compatible with 25,863 pathogen species, and the company claims it was the first to push identification from species level down to strain level. IDseq Focus is a probe-capture targeted sequencing product covering hundreds to thousands of pathogens and key resistance/virulence genes, aimed at suspected mild-to-moderate infections, with panels for lower respiratory tract, mycobacteria, and bloodstream infections. Beyond reagents, Vision Medicals has developed its own instruments and software. The VisionSeq 1000 is described as China's first gene sequencer covering both DNA and RNA sequencing in the pathogenic microorganism field, with dual-selectable flow cells (100M/500M reads), 9–10 hour sequencing runs, and DNBSEQ core technology; it holds NMPA registration (国械注准：20223220609). The company also offers MiLink · 云翼 for library preparation, MARS 3.0 and Solar System analysis software, and localization services. According to the company, it has obtained multiple NMPA medical device registration certificates and achieved full-process qualification certification spanning "detection reagents – sequencer – analysis software." Vision Medicals emphasizes industry-academia-research collaboration, stating partnerships with leading clinical institutions such as Peking Union Medical College Hospital, Chinese PLA General Hospital, Ruijin Hospital, Tongji Hospital, First Affiliated Hospital of Sun Yat-sen University, and the First Affiliated Hospital of Zhejiang University. It reports participation in nearly 20 national key R&D programs under the 14th and 15th Five-Year Plans and in industry standard setting, and co-founded the China Pathogen Metagenomics Interpretation Alliance. Its credentials include four consecutive years of full marks in the National Health Commission's mNGS external quality assessment, recognition as a national "specialized, refined, distinctive and innovative" (专精特新) enterprise, a Guangdong Provincial Enterprise Technology Center, and China Potential Unicorn status. It reports more than 70 patents, 30+ software copyrights, 120+ SCI papers, and 10+ expert consensus documents. The company remains privately held and is not listed on a stock exchange. Its recent news highlights include NMPA approval of a "globally new" respiratory mNGS detection reagent and an mNGS IVD kit receiving a Class III medical device registration certificate, alongside the inclusion of pathogen NGS in an expert consensus on the rational clinical application of multiplex pathogen detection for infectious diseases.

Vision Medicals was founded in 2018 in Guangzhou, China, according to its corporate introduction. From its inception, the company focused on genomic diagnostics and precision medicine for infectious diseases, an area where conventional culture-based and targeted molecular methods often fail to identify causative pathogens quickly enough for critically ill patients. The company built its technology around metagenomic next-generation sequencing (mNGS), which sequences all nucleic acids in a clinical sample without presetting targets, allowing unbiased detection of bacteria, fungi, viruses, and parasites. Its first flagship product, IDseq Prime, is described as a classic random-sequencing mNGS assay capable of detecting tens of thousands of pathogens in a single run, with strain-level typing and resistance/virulence gene detection. The company reports that it has accumulated over one million cases of pathogen big data, which it uses to refine its assays and databases. As the field matured, Vision Medicals expanded its portfolio. IDseq Ultra combines random and probe-capture sequencing (capture-enhanced mNGS), enriching more than 3,000 important pathogens while remaining broadly compatible with 25,863 pathogen species; the company states it was the first to push identification from species level down to strain level, and that key resistance/virulence gene detection capability improved two- to three-fold. IDseq Focus applies probe-capture targeted sequencing (tNGS) to enrich hundreds or thousands of pathogens and key resistance/virulence genes, with panels for lower respiratory tract (300+), mycobacteria (100+), and bloodstream infections, targeting suspected mild-to-moderate infections. Vision Medicals also moved into hardware and software. It developed the VisionSeq 1000, described as China's first gene sequencer covering both DNA and RNA sequencing in the pathogenic microorganism field, with dual-selectable flow cells (100M/500M reads), 9–10 hour runs, and DNBSEQ core technology; it holds NMPA registration (国械注准：20223220609). The company offers MiLink · 云翼 for library preparation, MARS 3.0 and Solar System analysis software, and localization services. According to the company, it has obtained multiple NMPA medical device registration certificates and achieved full-process qualification certification spanning "detection reagents – sequencer – analysis software." The company has pursued industry-academia-research collaboration, stating partnerships with leading hospitals including Peking Union Medical College Hospital, Chinese PLA General Hospital, Ruijin Hospital, Tongji Hospital, First Affiliated Hospital of Sun Yat-sen University, and the First Affiliated Hospital of Zhejiang University. It reports participation in nearly 20 national key R&D programs under the 14th and 15th Five-Year Plans and in industry standard setting, and co-founded the China Pathogen Metagenomics Interpretation Alliance. Its honors timeline, as listed on its website, includes: 2019 — national-level Guangdong technology-based SME, third prize in the 8th China Innovation and Entrepreneurship Competition (Guangdong), 2019 Future Healthcare 100 (China medical services top 100), and 2019 Guangdong-Hong Kong-Macao Greater Bay Area biomedical innovation enterprise top 50; 2020 — first prize in the Maker China anti-epidemic special competition, second prize in the 9th China Innovation and Entrepreneurship Competition, gold award in the Guangdong "Zhongchuang Cup" anti-epidemic special competition, third Guangdong-Hong Kong-Macao Greater Bay Area biomedical innovation enterprise top 50 pioneer enterprise, and 2020 Future Unicorn; 2021 — National High-Tech Enterprise certification, annual Future Healthcare 100, annual China healthcare best emerging top 10, 2021 Investment World healthcare VENTURE50, fourth Guangdong-Hong Kong-Macao Greater Bay Area biomedical innovation enterprise top 50, annual Guangzhou Rising Star, and Guangdong-Hong Kong-Macao Greater Bay Area new economy pioneer enterprise top 50; 2022 — Guangdong Provincial Infectious Disease Precision Diagnosis Engineering Technology Research Center, second prize in the 2022 China Innovation and Entrepreneurship Competition (Guangdong), 11th China Innovation and Entrepreneurship Competition excellence award, KPMG first biomedical innovation top 50 enterprises, and annual Guangzhou Development Zone gazelle enterprise; 2023 — 2023 Chinese Preventive Medicine Association Science and Technology First Prize, 12th China Innovation and Entrepreneurship Competition (Guangdong) second prize, China Potential Unicorn, 2023 Guangzhou high-tech high-growth top 20, Guangzhou innovative SME, and Guangdong specialized, refined, distinctive and innovative SME; 2024 — National Science and Technology Progress Second Prize and Guangzhou postdoctoral innovation base; 2025 — national specialized, refined, distinctive and innovative "little giant" enterprise, Guangdong Provincial Enterprise Technology Center, Henan Provincial Science and Technology Progress Second Prize, Zhejiang Provincial Science and Technology Progress Third Prize, Guangdong specialized, refined, distinctive and innovative SME, Zhejiang technology-based SME, Guangdong innovative SME, Guangdong technology-based SME, and Guangzhou Future Unicorn. The company reports more than 70 patents, 30+ software copyrights, 120+ SCI papers, and 10+ expert consensus documents, and states it has passed the National Health Commission's mNGS external quality assessment with full marks for four consecutive years. Recent news includes NMPA approval of a "globally new" respiratory mNGS detection reagent and an mNGS IVD kit receiving a Class III medical device registration certificate, as well as the inclusion of pathogen NGS in an expert consensus on the rational clinical application of multiplex pathogen detection for infectious diseases.

• 2026

  NMPA approves "globally new" respiratory mNGS detection reagent; mNGS detection kit receives NMPA Class III medical device registration certificate; pathogen NGS included in expert consensus on rational clinical application of multiplex pathogen detection for infectious diseases.

• 2025

  Named national specialized, refined, distinctive and innovative "little giant" enterprise; recognized as Guangdong Provincial Enterprise Technology Center; won Henan Provincial Science and Technology Progress Second Prize and Zhejiang Provincial Science and Technology Progress Third Prize.

• 2024

  Won National Science and Technology Progress Second Prize; established Guangzhou postdoctoral innovation base.

• 2023

  Won 2023 Chinese Preventive Medicine Association Science and Technology First Prize and 12th China Innovation and Entrepreneurship Competition (Guangdong) second prize; named China Potential Unicorn and 2023 Guangzhou high-tech high-growth top 20.

• 2022

  Established Guangdong Provincial Infectious Disease Precision Diagnosis Engineering Technology Research Center; won second prize in 2022 China Innovation and Entrepreneurship Competition (Guangdong); named KPMG first biomedical innovation top 50 enterprise and annual Guangzhou Development Zone gazelle enterprise.

• 2021

  Certified as National High-Tech Enterprise; listed in annual Future Healthcare 100, China healthcare best emerging top 10, 2021 Investment World healthcare VENTURE50, and Guangdong-Hong Kong-Macao Greater Bay Area new economy pioneer enterprise top 50.

• 2020

  Won first prize in Maker China anti-epidemic special competition, second prize in the 9th China Innovation and Entrepreneurship Competition, and gold award in Guangdong "Zhongchuang Cup" anti-epidemic special competition; named 2020 Future Unicorn.

• 2019

  Recognized as national-level Guangdong technology-based SME; won third prize in the 8th China Innovation and Entrepreneurship Competition (Guangdong); listed in 2019 Future Healthcare 100 and 2019 Guangdong-Hong Kong-Macao Greater Bay Area biomedical innovation enterprise top 50.

• 2018

  Vision Medicals founded in Guangzhou, China.

AI-driven infectious disease diagnostics; full-process mNGS solution spanning reagents, sequencer, and analysis software, with a focus on precision pathogen diagnosis.

• IDseq Prime

  Classic pathogen metagenomic next-generation sequencing (mNGS) product based on random sequencing; detects tens of thousands of bacteria, fungi, viruses, and parasites in one unbiased run, with strain-level typing and resistance/virulence gene detection. Core advantages: dual workflow reporting within 10 hours, Patho-NET host depletion technology, China-customized database.

• IDseq Ultra

  Capture-enhanced mNGS product combining random and probe-capture sequencing; enriches 3,000+ important pathogens while remaining broadly compatible with 25,863 pathogen species; company states it is the first to push identification from species to strain level, with 2–3x improvement in key resistance/virulence gene detection.

• IDseq Focus

  Probe-capture targeted sequencing (tNGS) product enriching hundreds to thousands of pathogens and key resistance/virulence genes; panels include lower respiratory tract 300+, mycobacteria 100+, and bloodstream infection; detection limit as low as 30 copies/mL, covering 90%+ of common clinically important pathogens.

• VisionSeq 1000

  China's first gene sequencer covering both DNA and RNA sequencing in the pathogenic microorganism field; dual-selectable flow cells (100M/500M reads), 9–10 hour sequencing, DNBSEQ core technology; NMPA registration 国械注准：20223220609.

• MiLink · 云翼

  Library preparation solution for mNGS workflows (nucleic acid in, library out).

• MARS 3.0

  Analysis software for pathogen NGS data.

• Solar System

  Analysis software for pathogen NGS data.

1. 1微远基因 - 专注病原精准诊断visionmedicals.com
2. 2企业荣誉 - 微远基因visionmedicals.com
3. 3企业介绍 - 微远基因visionmedicals.com
4. 4产品中心 - 微远基因visionmedicals.com
5. 5Vision Medicals (China) - Wikidatawikidata.org